Insider · CIK 0001880129
Christopher John Kenney
Files at XENE (Xenon Pharmaceuticals Inc.). First filing Mar 11, 2026, latest Mar 13, 2026.
Christopher John Kenney files SEC Form 4 as officer at XENE (Xenon Pharmaceuticals Inc.). Since Mar 11, 2026, Christopher John Kenney has reported 0 open-market buys worth $0 and 2 open-market sells worth $244k, the latest filed on Mar 13, 2026.
A track record needs three past buys with six months of prices behind them; Christopher John Kenney has 0, so none is measured yet.
The newest scored trade: sold $78k of XENE on Mar 13, 2026, filed Mar 13, 2026, scored 9 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $244k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XENE: Xenon Pharmaceuticals Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 9Weak | Xenon Pharmaceuticals Inc. | $78k 1,410 shares | -17% | +96% from low-12% from high | |
| 16Weak | Xenon Pharmaceuticals Inc. | $167k 2,771 shares | -37% | +115% from low-3% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 13, 2026 | XENE Xenon Pharmaceuticals Inc. | 1,410 0.00% of outstanding | $78k | Mar 13, 2026 | $167k |
| Mar 10, 2026 | XENE Xenon Pharmaceuticals Inc. | 2,771 0.00% of outstanding | $167k | Mar 10, 2026 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +3,750 | - | - | 8,479 | Mar 13, 2026 |
| Mar 13, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -1,410 | $55.23 | $78k | 7,069 | Mar 13, 2026 |
| Mar 12, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Restricted Share Unitsderivative10b5-1 | -3,750 | $0.00 | $0 | 11,250 | Mar 13, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +7,500 | - | - | 7,500 | Mar 11, 2026 |
| Mar 10, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -2,771 | $60.11 | $167k | 4,729 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Performance Share Unitsderivative10b5-1 | +7,500 | $0.00 | $0 | 7,500 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Performance Share Unitsderivative10b5-1 | -7,500 | $0.00 | $0 | 0 | Mar 11, 2026 |
| Jan 9, 2026 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Share Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 9, 2026 |
| Jan 9, 2026 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Restricted Share Unitsderivative | +20,000 | $0.00 | $0 | 20,000 | Jan 9, 2026 |
| Mar 12, 2025 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Share Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Mar 13, 2025 |
| Mar 12, 2025 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Restricted Share Unitsderivative | +15,000 | $0.00 | $0 | 15,000 | Mar 13, 2025 |
Questions about Christopher John Kenney
Answered from the filings on this page, as of the latest one.
Is Christopher John Kenney buying or selling?
In the last 12 months Christopher John Kenney reported 0 open-market buys worth $0 and 2 open-market sells worth $244k on SEC Form 4; the latest was sold $78k of XENE on Mar 13, 2026. Grants, option exercises and tax withholding are not counted.
How did Christopher John Kenney's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher John Kenney has 0.
Where does Christopher John Kenney file Form 4?
Christopher John Kenney has filed Form 4 at XENE (Xenon Pharmaceuticals Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.